Recent News

• 11.05.2026 - CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
• 11.02.2026 - CytomX Therapeutics to Present at Upcoming November Investor Conferences
• 10.29.2026 - CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026
• 09.01.2026 - CytomX Therapeutics to Present at Upcoming September Investor Conferences
• 08.27.2026 - CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
• 08.06.2026 - CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
• 08.03.2026 - CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
• 07.27.2026 - CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
• 06.03.2026 - CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
• 05.21.2026 - CytomX Therapeutics to Present at Upcoming June Investor Conferences

Recent Filings

• 10.28.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.16.2026 - 4/A Statement of changes in beneficial ownership of securities
• 08.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.07.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.06.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 08.06.2026 - 8-K Current report
• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - EX-99.1 EX-99.1
• 08.05.2026 - 4 Statement of changes in beneficial ownership of securities